TL;DR
Get workout gear delivered free with Prime
- Fast, free delivery on millions of items
- Prime Video, Amazon Music and more included
- Member-only deals all year
A prospective study of 276 people with HPV-positive oropharyngeal cancer found durable outcomes after chemoradiation that reduced elective nodal radiation to 30 Gy and omitted selected low-risk nodal regions. At a median five-year follow-up, locoregional control was 97% and overall survival was 90.8%; the regimen still needs confirmation in a multicenter phase III trial.
A prospective study of 276 patients with HPV-positive oropharyngeal cancer found durable cancer control after a reduced-intensity radiation approach, with 97% five-year locoregional control and 90.8% overall survival. The strategy lowered radiation to elective nodal regions to 30 Gy and omitted selected low-risk nodal areas, but researchers say it requires confirmation in a multicenter phase III trial before it can be established as a standard approach.
The study, reported by Nancy Y. Lee of Memorial Sloan Kettering Cancer Center and colleagues in JAMA Oncology, followed patients for a median of five years. Patients received definitive concurrent chemoradiation, predominantly with platinum-based chemotherapy. Of the 276 participants, 256 received intensity-modulated radiotherapy and 20 received intensity-modulated proton therapy.
Under the regimen, elective nodal and subclinical regions received 30 Gy in 15 fractions, followed by a sequential boost of 40 Gy in 20 fractions. The approach also omitted selected low-risk nodal basins, including levels IB and V. The study reported 85.9% five-year progression-free survival and 91.2% distant metastasis-free survival. At five years, 260 patients had no evidence of disease; 250 were alive at their last follow-up.
The report recorded one elective nodal failure: a contralateral indeterminate lymph node visible at baseline that had received 30 Gy. The authors said no failures occurred in nodal basins omitted from treatment. There were distant-only recurrences in 23 patients. These findings describe outcomes in this study group; they do not establish that the regimen is appropriate for every patient with HPV-related throat cancer.
Reducing Radiation to Healthy Tissue
Elective nodal irradiation treats lymph-node areas considered at risk even when they do not contain visible cancer. Lowering its dose or excluding selected regions may reduce radiation exposure to normal structures involved in saliva production and swallowing, which can affect patients during and after treatment. The study adds long-term outcome data to evidence that these areas may not always need the conventional radiation dose.
External expert David Sher of UT Southwestern Medical Center, who was not involved in the study, said elective nodal radiation contributes to exposure of normal tissue and critical structures. He described the outcomes as striking given the degree of dose reduction, while also noting that the study did not provide quality-of-life data. The findings suggest a possible way to reduce treatment burden, but they do not by themselves prove that patients experience fewer side effects or that cancer control is equivalent across settings.
The distinction matters because treatment de-escalation must preserve the chance of cure. Sher said a multicenter randomized phase III study is needed to confirm non-inferiority before this regimen can become a standard of care. Until then, the results are evidence supporting further evaluation, not a general instruction to reduce treatment.
Products Worth Considering
Oral-B iO Series 5 Rechargeable Electric Toothbrush with 3 Brush Heads and Travel Case, Black
Hyperice Hypervolt 3 Pro Percussion Massage Gun with Heated Head and Carry Case
Oral-B iO Series 3 Rechargeable Electric Toothbrush for Adults, Black
As an affiliate, we earn on qualifying purchases.
How the Reduced-Dose Strategy Was Tested
Lee and colleagues had previously reported two-year outcomes from the same de-escalation strategy, including favorable cancer control and quality-of-life results. The new report was designed to assess whether those outcomes remained durable over longer follow-up. Its five-year results extend the earlier evidence but do not replace the need for a direct, larger comparative trial.
Sher pointed to several features relevant to interpreting the results: all patients had PET-CT imaging, most also had MRI, and participants received cisplatin-containing chemotherapy. He said imaging may help identify smaller lymph nodes that could need higher doses, while the cancer’s sensitivity to cisplatin may also matter. The article did not report how many equivocal lymph nodes received a higher radiation dose.
The investigators reported that outcomes were attained across T- and N-stage groups and smoking histories in a population treated predominantly with concurrent platinum-based chemoradiation. Their report also cited prior phase III evidence favoring concurrent platinum chemotherapy for cure in HPV-associated oropharyngeal cancer. The tested change was therefore focused on elective nodal radiation within a curative treatment plan, rather than removing chemotherapy from the regimen.
“While we often focus on the total dose delivered to visible cancer, in actuality, ENI is responsible for a substantial amount of normal tissue irradiation and dose to critical normal structures, such as the salivary glands and swallowing structures.”
— David Sher, UT Southwestern Medical Center, speaking to MedPage Today
Limits of the Five-Year Evidence
The study reports outcomes after one treatment strategy but does not, in the supplied report, provide a randomized comparison showing that it is non-inferior to standard elective nodal radiation. Its results therefore cannot settle whether the reduced regimen should replace standard treatment. A multicenter phase III trial is needed to test that question across institutions.
Other details also limit interpretation. The study report did not provide quality-of-life data for this follow-up, and the number of equivocal lymph nodes given higher doses was not reported. Although Sher said prior reports of reduced nodal radiation had favorable quality-of-life findings, those observations should not be treated as a quality-of-life result from this study itself. The report also does not establish how outcomes would vary for patients treated without the imaging and cisplatin-based chemotherapy used in this group.
The Trial Needed for Wider Use
The next evidentiary step is a multicenter randomized phase III trial testing whether the reduced elective nodal dose preserves cancer control compared with standard treatment. Sher said such a trial would be needed to confirm non-inferiority and expressed hope that one could become available to patients and the clinical community. The source report does not identify a trial launch date or provide details of a specific planned study.
Until comparative results are available, clinicians and patients will need to interpret the five-year findings as supportive but not definitive. Any treatment decision depends on the individual case and specialist guidance; the study alone does not establish a new standard of care.
Key Questions
What did the study find after five years?
At a median follow-up of five years, reported outcomes included 97% locoregional control, 90.8% overall survival, 91.2% distant metastasis-free survival and 85.9% progression-free survival.
How was treatment reduced?
Elective nodal and subclinical regions received 30 Gy in 15 fractions, followed by a boost to treated areas. The approach also omitted selected low-risk nodal regions, including levels IB and V.
Does the study prove reduced radiation is the new standard?
No. The findings support further investigation, but an expert quoted in the report said a multicenter randomized phase III trial is needed to confirm non-inferiority before the regimen can become standard care.
Did the report show that patients had fewer side effects?
The study report did not provide quality-of-life data for this follow-up. Reduced exposure to normal tissues may be relevant to side effects, but this report does not establish that patients experienced fewer side effects.
Who was included in the study?
The analysis included 276 patients with HPV-positive oropharyngeal cancer. All received concurrent chemoradiation, predominantly with platinum-based chemotherapy; 256 received intensity-modulated radiotherapy and 20 received proton therapy.
Source: medpagetoday.com
